GlassScriptPhysician profile
Layne Keathly
NPI 1760802177
$9,800.82
in general payments reported to CMS, 2019-2025
44 companies · $2,019 in 2025
The $2,019 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,969 · 2020: $579 · 2021: $162 · 2022: $1,419 · 2023: $1,927 · 2024: $1,726 · 2025: $2,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,671.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,340.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,082.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,002.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $894.64 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $892.44 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $608.70 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $379.57 | 2019-2024 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $351.48 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Merck Sharp & Dohme LLC | $323.13 | 2019-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $309.70 | 2019-2025 | Spravato |
| Astellas Pharma US INC | $244.31 | 2020-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $235.18 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.51 | 2019-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $186.23 | 2019-2023 | |
| Lundbeck LLC | $173.20 | 2024-2025 | Vyepti, Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Keathly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.